Cybersecurity solutions company, BrandShield has signed a contract with a major pharmaceutical firm on Wednesday.
BrandShield Systems has announced the signing of a new deal with a major pharmaceutical manufacturer. The deal follows a period of continued sales growth and the signing of several new customers since the start of 2022.
BrandShield will provide enhanced brand protection for the pharmaceutical company, using its highly automated SaaS product to detect and eliminate online risks such as fraudulent pharmacies.
Geographically, BrandShield will focus on using its innovative software services to protect the pharmaceutical company’s operations from cybercriminals across Asia and Oceania, as well as safeguarding users and improving the customer experience.
The mandate adds to BrandShield’s growing roster of pharmaceutical clients, which includes collaborations with the Pharmaceutical Security Institute and Bristol-Myers Squibb to detect and remove rogue pharmacies and fake medicine listings from the internet.
Yoav Keren, Chief Executive Officer, BrandShield said, “This win is an example of one of several new mandates BrandShield has already secured in 2022, strengthening our reputation as a leading provider of digital risk protection solutions for companies across a wide array of sectors.”
“BrandShield has a proven track record of successfully identifying and eradicating critical online threats to global pharmaceutical companies and we look forward to extending our leading position in the pharmaceutical space, one of many exciting opportunities in our pipeline for the near to medium term.”
BrandShield shares gained 2% to 10.8p following the news of its new deal with a leading pharmaceutical company on Wednesday.